Henriksen Daniel Pilsgaard, Stage Tore Bjerregaard, Hansen Morten Rix, Rasmussen Lotte, Damkier Per, Pottegård Anton
Department of Clinical Chemistry and Pharmacology, Odense University Hospital, Odense, Denmark.
Clinical Pharmacology, Department of Public Health, University of Southern Denmark, Odense, Denmark.
Pharmacoepidemiol Drug Saf. 2015 Dec;24(12):1337-40. doi: 10.1002/pds.3881. Epub 2015 Sep 23.
Proton pump inhibitors (PPIs) have been suggested to increase the effect of warfarin, and clinical guidelines recommend careful monitoring of international normalized ratio (INR) when initiating PPI among warfarin users. However, this drug-drug interaction is sparsely investigated in a clinical setting. The aim was to assess whether initiation of PPI treatment among users of warfarin leads to increased INR values.
The study was an observational self-controlled study from 1998 to 2012 leveraging data on INR measurements on patients treated with warfarin from primary care and outpatient clinics and their use of prescription drugs. Data were analyzed in 2015. We assessed INR, warfarin dose, and dose/INR ratio before and after initiating PPI treatment using the paired student's t-test.
We identified 305 warfarin users initiating treatment with PPIs. The median age was 71 years (interquartile range 63-78 years), and 64% were men. The mean INR in the 70 days prior to PPI initiation was 2.6 (95%CI 2.5-2.8) and 2.6 (95%CI 2.5-2.7) in the period 1-3 weeks after PPI initiation (p = 0.67). Further, neither mean warfarin dose nor the dose/INR ratios were significantly different before and after PPI initiation. Sensitivity analyses revealed no differences among individual PPIs.
We found no evidence of a clinically meaningful drug-drug interaction between PPIs and warfarin in a Northern European patient population of unselected patients from an everyday outpatient and primary care clinical setting. Thus, we do not support the recommendation to "cautiously monitor" users of warfarin initiating PPI treatment.
质子泵抑制剂(PPIs)被认为可增强华法林的作用,临床指南建议,在华法林使用者开始使用PPIs时,应密切监测国际标准化比值(INR)。然而,这种药物相互作用在临床环境中的研究较少。本研究旨在评估华法林使用者开始使用PPI治疗是否会导致INR值升高。
本研究为一项观察性自身对照研究,时间跨度为1998年至2012年,利用基层医疗和门诊诊所接受华法林治疗患者的INR测量数据以及他们的处方药使用情况。数据于2015年进行分析。我们使用配对学生t检验评估开始PPI治疗前后的INR、华法林剂量和剂量/INR比值。
我们确定了305名开始使用PPIs治疗的华法林使用者。中位年龄为71岁(四分位间距63 - 78岁),64%为男性。开始使用PPI前70天的平均INR为2.6(95%CI 2.5 - 2.8),开始使用PPI后1 - 3周期间为2.6(95%CI 2.5 - 2.7)(p = 0.67)。此外,开始使用PPI前后的平均华法林剂量和剂量/INR比值均无显著差异。敏感性分析显示各PPI之间无差异。
在北欧日常门诊和基层医疗临床环境中,未选择的患者群体中,我们未发现PPI与华法林之间存在具有临床意义的药物相互作用的证据。因此,我们不支持“密切监测”开始使用PPI治疗的华法林使用者这一建议。